Comparative Pharmacology
Head-to-head clinical analysis: MOXEZA versus NOROXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXEZA versus NOROXIN.
MOXEZA vs NOROXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
400 mg orally once daily with or without food.
400 mg orally twice daily for 3-14 days depending on indication.
None Documented
None Documented
Terminal half-life: 12 hours; allows once-daily dosing
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic